In Vitro Diagnostics: Technologies and Global Markets

Report Highlights

The global market for In Vitro Diagnostics (IVD) is expected to grow from $94.7 billion in 2024 and is projected to reach $141.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.4% during the forecast period of 2024 to 2029.

Report Includes

• 41 data tables and 54 additional tables
• Analysis of global market trends, with data from 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
• Estimates of the size of the market for in vitro diagnostics (IVD) technologies, revenues, and market shares by technology, product, application, end user and region
• Assessment of market dynamics such as drivers, restraints and opportunities
• Discussion of how the rise in the number of respiratory infections, hospital acquired infections (HAIs), and sexually transmitted diseases are creating a constant need for IVD testing in hospitals and laboratories
• Discussion of IVD for neglected infectious diseases, chemistry-based portable analysis and microfluidic platform-based POC tests
• A discussion on ESG challenges and practices in the industry
• Assessment of the competitive landscape, including the market shares of key companies, their product portfolios and financial overviews
• Information on recent mergers, acquisitions, expansions, collaborations, investments, divestments and product launches
• Profiles of the leading companies, including F. Hoffmann-La Roche Ltd., Abbott, Sysmex Corp., Danaher, BD, and Siemens Healthineers AG

Report Scope

This report covers the in vitro diagnostic (IVD) technologies as well as in vitro diagnostic devices used in hospitals and point-of-care (POC) facilities to diagnose diseases. It also details the current and future market potential of in vitro diagnostic technology and includes an analysis of this market’s competitive environment. The report covers market drivers, restraints, opportunities, product approvals, regulatory scenario assessments and emerging technologies. It features market projections and estimates of the market shares of key players through 2029.

In this analysis, the in vitro diagnostics market is segmented based on technologies, applications, end users and region. Based on technologies, the market is segmented into the following categories: hematology, immunochemistry, molecular diagnostics, POC testing, clinical microbiology and tissue diagnostics. Based on applications, the in vitro diagnostics market is segmented into these categories: diabetes, nephrology, blood glucose evaluation and monitoring (BGEM), oncology, cardiology, infectious diseases and other applications. The market is segmented based on end users into diagnostic laboratories, hospitals and clinics, point-of-care centers, and other end users.

The global in vitro diagnostics market has been segmented by the following geographical regions: North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. The report features detailed analyses of major countries such as the U.S., Germany, the U.K., Italy, France, Spain, Japan, China, India, Australia and New Zealand (ANZ), Argentina, Brazil, South Africa, Mexico and the GCC countries. Market analysis data is provided for 2023, which serves as the base year, and estimates are given for 2024 and forecast values through 2029.

Analyst Credentials

Partha Sarathi Das– Associate Consultant-Life Science Research
Partha Sarathi has an experience of nearly a decade in multiple domains, including healthcare, life science, biotechnology, pharmaceuticals, and healthcare IT. His expertise is in designing research studies, gathering data, and performing analysis, ultimately providing clients with actionable insights and recommendations based on their unique business needs. Designs proposal and participates in client queries for quick delivery based on their unique business needs. Academically, Parthasarathi holds a master’s degree in Biotechnology and a bachelor’s degree in Industrial Biotechnology.

Consulting Editor’s Credentials

Dr. Marianna Tcherpakov has more than 10 years of experience as a bench scientist specializing in the areas of biochemistry, cell biology, assay development, antibody and drug manufacturing. She has authored several scientific publications in peer review journals. In the last 10 years, Marianna worked as a business development professional in CRO/CDMO industry. She is familiar with pharmaceutical and biotech landscape, trends and potential future developments in industry.